<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:SBBP (USA) Also Trade In: Germany

Strongbridge Biopharma PLC $ 1.94 0.01 (0.52%)

Volume:
96,316
Avg Vol (1m):
176,943
Market Cap $:
105.12 Mil
Enterprise Value $:
20.56 Mil
P/E (TTM):
4.31
P/B:
1.11
Warning! GuruFocus has detected 3 Severe warning signs with SBBP. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)

SBBP News and Headlines - Strongbridge Biopharma PLC

GuruFocus Articles Total 46
  • 1
  • 2
  • 3

DUBLIN, Ireland and TREVOSE, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that long-term efficacy and safety characterization results for KEVEYIS® (dichlorphenamide), the first and only U.S. Food and Drug Administration (FDA) approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP), will be presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting held

0 Views    Marketwired    2019-10-17 12:00

DUBLIN, Ireland and TREVOSE, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, will present at the 2019 Cantor Global Healthcare Conference.  The details of the conferences are as follows:

2019 Cantor Global Healthcare Conference
Friday, October 4 at 8:55 am ET
InterContinental New York Barclay, New York, NY

The Company’s presentation will

0 Views    Marketwired    2019-09-25 16:00

~ RECORLEV Resulted in Sustained Improvements in Urinary Free Cortisol (UFC) and Provided Clinical Benefit, As Demonstrated By Improvements in Comorbidities and Characteristic Signs and Symptoms of Cushing’s Syndrome ~

~ RECORLEV Was Generally Well-Tolerated, With No Unexpected Safety Signals Observed ~

DUBLIN, Ireland and TREVOSE, Pa., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that comprehensive results from

0 Views    Marketwired    2019-09-19 12:00

DUBLIN, Ireland and TREVOSE, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference and the Janney Montgomery Scott Healthcare Conference 2019.  The details of the conferences are as follows:

H.C. Wainwright 21st Annual Global Investment Conference
Monday, September 9 at 1:45 pm

0 Views    Marketwired    2019-09-03 12:00

~ Richard S. Kollender Appointed to Chief Operating Officer ~

~ Robert Lutz Promoted to Chief Financial Officer ~

~ David Gill Appointed to Board of Directors ~

DUBLIN, Ireland and TREVOSE, Pa., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced key leadership changes, including the appointment of Richard S. Kollender, who previously served on the Company’s board

0 Views    Marketwired    2019-08-13 16:03

DUBLIN, Ireland and TREVOSE, Pa., July 24, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Wednesday, July 31 at 8:30 a.m. ET to discuss the Company’s second quarter 2019 financial results and corporate highlights. The conference call will follow the anticipated release of the Company’s financial results earlier that

0 Views    Marketwired    2019-07-24 12:14

DUBLIN, Ireland and TREVOSE, Pa., July 19, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awards to eight individuals who have recently become, or are expected to become, employees of the Company. 

The inducement awards are being made in the form of non-qualified stock options to purchase an aggregate of 208,500 ordinary shares of the Company

0 Views    Marketwired    2019-07-19 12:00

DUBLIN, Ireland and TREVOSE, Pa., July 01, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has been added to the U.S. broad-market Russell 3000® and Microcap® Indexes at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open on Monday, July 1, 2019.

The Russell annual index rebalance process captures the 4,000 largest U.S. stocks as

0 Views    Marketwired    2019-07-01 12:00

DUBLIN, Ireland and TREVOSE, Pa., June 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the 2019 JMP Securities Life Sciences Conference taking place June 19-20 at the St. Regis Hotel in New York, NY.

Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Wednesday, June 19 at 11:00am E.T.

0 Views    Marketwired    2019-06-12 12:00

Scott Wilhoit Promoted to Chief Commercial Officer

Marcy Nanus Appointed Vice President of Corporate Affairs

DUBLIN, Ireland and TREVOSE, Pa., June 04, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the promotion of Scott Wilhoit to chief commercial officer. Scott previously served as senior vice president of global market access, patient services and advocacy. The Company also announced the appointment of

0 Views    Marketwired    2019-06-04 12:00

DUBLIN, Ireland and TREVOSE, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the Jefferies 2019 Global Healthcare Conference taking place June 4-7 at the Grand Hyatt in New York, NY.

Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Thursday, June 6 at 8:30am E.T. The presentation

0 Views    Marketwired    2019-05-30 12:00

~ Results Demonstrate Long-term Treatment with KEVEYIS is Efficacious and Provides Durable Reduction in Attack Frequency and Severity in Patients with PPP ~

DUBLIN, Ireland and TREVOSE, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that long-term efficacy results for KEVEYIS® (dichlorphenamide), the first and only U.S. Food and Drug Administration (FDA) approved treatment for hyperkalemic, hypokalemic, and related

0 Views    Marketwired    2019-05-10 00:03

New Analysis Shows RECORLEV™ (levoketoconazole) Significantly Improved Clinician- and Patient-Reported Signs and Symptoms of Cushing’s Syndrome

DUBLIN, Ireland and TREVOSE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the presentation of new secondary endpoint results from the Phase 3 SONICS study of RECORLEV™ (levoketoconazole) for the potential treatment of endogenous Cushing’s syndrome at the 2019 American Association of

0 Views    Marketwired    2019-04-26 00:00

DUBLIN, Ireland and TREVOSE, Pa., April 24, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Wednesday, May 1 at 8:30 a.m. ET to discuss the Company’s first quarter 2019 financial results and corporate highlights. The conference call will follow the anticipated release of the Company’s financial results earlier that

0 Views    Marketwired    2019-04-24 12:00

DUBLIN, Ireland and TREVOSE, Pa., April 15, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will present new secondary endpoint results from the Phase 3 SONICS study of RECORLEV™ (levoketoconazole) for the potential treatment of endogenous Cushing’s syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual Scientific and Clinical Congress, held April 24 – 28, in Los Angeles, California.

0 Views    Marketwired    2019-04-15 12:00

NEW YORK, April 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cemex S.A.B. de C.V. (:CX), Strongbridge Biopharma PLC (SBBP), Overseas Shipholding Group, Inc. (:OSG), Ritter Pharmaceuticals, Inc. (RTTR), AAC Holdings, Inc. (:AAC), and Gamco Investors, Inc. (:GBL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at

0 Views    Marketwired    2019-04-12 16:00

~ Subgroup Analysis of Patients with Comorbid Diabetes Mellitus and Cushing’s Syndrome Presented at Annual Meeting of the Endocrine Society (ENDO) Shows Potential Clinical Benefit of Treatment with RECORLEV™ (levoketoconazole) ~

~ Additional Analyses of RECORLEV Secondary Endpoints Presented at 16th Annual International Pituitary Congress Continue to Demonstrate Clinically Meaningful Improvements in Cortisol Control ~

DUBLIN, Ireland and TREVOSE, Pa., March 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies

0 Views    Marketwired    2019-03-25 12:00

~ Extended Evaluation Phase Meets Objective of Showing Positive Long-Term Benefit-Risk Profile of RECORLEV™ (levoketoconazole) ~

~ Favorable Liver-Related Findings: No Patients Experienced an Increase in Either Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) of Greater than Three Times the Upper Limit of Normal During the Extended Evaluation Phase ~

~ Long-Term Efficacy Results of RECORLEV™ (levoketoconazole) Continue to Demonstrate Clinically Meaningful Improvements in Mean Urinary Free Cortisol (mUFC) and Key Cardiovascular Risk Markers ~

DUBLIN, Ireland and TREVOSE, Pa., March 11, 2019

0 Views    Marketwired    2019-03-11 12:04

DUBLIN, Ireland and TREVOSE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awards to 15 individuals who have recently become, or are expected to become, employees of the Company. 

The inducement awards are being made in the form of non-qualified stock options to purchase an aggregate of 309,300 ordinary shares of the Company,

0 Views    Marketwired    2019-03-08 13:01

DUBLIN, Ireland and TREVOSE, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, ( SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that a new subset analysis from the previously reported Phase 3 SONICS study of RECORLEV™ (levoketoconazole) in patients with endogenous Cushing’s syndrome will be presented in a poster session at the Annual Meeting of the Endocrine Society (ENDO), taking place in New Orleans, Louisiana from March 23 -

0 Views    Marketwired    2019-03-04 13:00

Headlines Total 80
  • 1

2019-10-23 $ 1.94 (0.52%)
9:33am
2019-10-17 $ 2.01 (-0.5%)
7:00am
2019-10-04 $ 2.27 (-1.3%)
11:23am
2019-09-25 $ 2.54 (-1.17%)
11:00am
2019-09-19 $ 2.74 (-1.08%)
7:00am
2019-09-11 $ 2.8 (-2.44%)
1:11pm
2019-09-03 $ 2.57 (-0.77%)
7:00am
2019-08-13 $ 2.67 (4.3%)
11:03am
2019-07-31 $ 2.6 (-4.06%)
2:25pm
8:15am
2019-07-24 $ 2.6 (2.36%)
7:14am
2019-07-19 $ 2.77 (-1.77%)
7:00am
2019-07-18 $ 2.82 (-2.42%)
2:08pm
2019-07-01 $ 3.38 (7.99%)
7:00am
2019-06-12 $ 3.15 (5%)
7:00am
2019-06-11 $ 3 (0.33%)
10:58pm
2019-06-07 $ 3.01 (6.74%)
3:55pm
2019-06-04 $ 2.85 (-1.38%)
7:00am
2019-05-30 $ 2.91 (1.04%)
7:00am
2019-05-09 $ 3.29 (-5.46%)
7:03pm
2019-05-02 $ 3.66 (-3.43%)
12:23am
2019-05-01 $ 3.79 (-20.88%)
12:33pm
12:16pm
11:12am
2019-04-25 $ 4.74 (1.28%)
7:00pm
2019-04-24 $ 4.68 (3.77%)
7:00am
2019-04-15 $ 4.64 (-0.43%)
7:00am
2019-03-25 $ 4.79 (-6.99%)
7:00am
2019-03-12 $ 5.35 (-3.08%)
3:52pm
2019-03-11 $ 5.52 (9.09%)
7:04am
2019-03-08 $ 5.06 (-1.36%)
7:01am
2019-03-05 $ 5.25 (-0.57%)
12:13pm
2019-03-04 $ 5.28 (-2.76%)
7:58am
7:00am
2019-02-27 $ 5.15 (5.32%)
7:03am
2019-02-26 $ 4.89 (-1.01%)
12:51pm
2019-02-22 $ 4.75 (2.37%)
7:01am
2019-02-19 $ 4.66 (-1.69%)
7:03am
2019-01-28 $ 4.68 (-2.3%)
9:51am
2018-12-19 $ 4.15 (-1.43%)
7:02am
2018-11-20 $ 5.1 (1.19%)
7:03am
2018-11-05 $ 5.88 (0.68%)
7:03pm
2018-11-02 $ 5.84 (-1.35%)
9:09pm
2018-10-31 $ 6.4 (58.02%)
11:02am
9:10am
2018-10-22 $ 4.75 (-2.46%)
7:03am
2018-09-18 $ 4 (-2.44%)
7:01am
2018-08-28 $ 5.45 (%)
7:02am
7:01am
2018-08-15 $ 5.05 (-19.2%)
7:00pm
2018-08-14 $ 6.25 (4.17%)
7:00pm
2018-08-12
7:34am
3:31am
2018-08-08 $ 5.9 (31.11%)
7:07am
7:00am
2018-06-06 $ 6.7 (2.29%)
7:00am
2018-05-31 $ 6.5 (-7.14%)
7:03am
2018-05-18 $ 7.7 (%)
8:41am
2018-05-06
1:42am
2018-05-03 $ 7.85 (%)
7:03am
2018-04-26 $ 7.4 (1.37%)
7:03am
2018-04-02 $ 8.4 (-5.08%)
7:01am
2018-03-26 $ 8.2 (1.86%)
7:01am
2018-03-18
7:30am
2018-01-26 $ 6.95 (-3.47%)
1:01pm
2018-01-24 $ 7.85 (-9.77%)
6:07am
2018-01-22 $ 8.45 (-1.17%)
1:23am
2018-01-18 $ 7.85 (%)
10:18am
2017-12-04 $ 6.3 (-6.67%)
8:07am
2017-11-22 $ 6.55 (3.15%)
3:21am
2017-11-17 $ 5.65 (4.63%)
1:09pm
2017-11-16 $ 5.4 (0.93%)
10:30pm
2017-11-07 $ 5.95 (-3.25%)
10:07am
2017-10-11 $ 6.25 (-0.79%)
12:55pm
2017-09-12 $ 6.25 (0.81%)
1:37pm
2017-08-11 $ 7.05 (6.82%)
12:58pm
2017-04-10 $ 4.2 (1.2%)
1:00pm
1969-12-31
7:00pm
m - realmoney.thestreet.com
7:00pm
7:00pm
Total 80
  • 1